Varex Imaging (VREX) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $0.31
- Estimate
- $0.20
- Surprise
- +56.6%
- Revenue (period 2026-07-03)
- $210.5M
- Score at report (before → after)
- 5.7 → 5.9/10
Revenue source: xbrl.
How the report landed
Varex Imaging (VREX) beat the $0.20 estimate with diluted EPS of $0.31 — a large 56.6% upside surprise. TrendMatrix's engine moved from Sell (5.7/10) to Hold at 5.9/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates VREX Sell at 5.5/10.
3 of the last 4 quarters beat the estimate; this quarter's +56.6% surprise compares with a +70.0% four-quarter average. Next scheduled report: 2026-11-17.
What argues against it
- Target reached (-13.1% upside)
- Quality below floor (4.0 < 4.0)
- Negative risk/reward — downside exceeds upside
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $18.51
- Price target
- $21.29
- Stop
- $17.29
- Upside to target
- +15.0%
The stock trades at 34.9× trailing but 16.9× forward earnings — consensus estimates already build in a substantial earnings recovery.
Risk check: RSI 96 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.
VREX at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Devices
- Market cap
- $780.2M
- P/E (fwd)
- 16.9
- P/E (ttm)
- 34.9
- 52-week range
- $9.09–$18.63
- Off 52-week high
- 0.6%
- RSI (14)
- 96
- Volume vs avg
- 0.67×
- Score today
- 5.5/10